Dovitinib (CHIR258, TKI258): Structure, Development and Preclinical and Clinical Activity

References

• Kaelin WG Jr . The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer8, 865–873 (2008).
   PubMed Web of Science ®Google Scholar
• Brugarolas J . Renal-cell carcinoma. Molecular pathways and therapies. N. Engl. J. Med.356, 185–187 (2007).
   PubMed Web of Science ®Google Scholar
• Majmundar AJ , WongWJ, SimonMC. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell40, 294–309 (2010).
   PubMed Web of Science ®Google Scholar
• Baldewijns MM , van VlodropIJ, SchoutenLJ, SoetekouwPM, de BruineAP, van EngelandM. Genetics and epigenetics of renal cell cancer. Biochim. Biophys. Acta1785, 133–155 (2008).
   PubMed Web of Science ®Google Scholar
• Rini BI , AtkinsMB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol.10, 992–1000 (2009).
   PubMed Web of Science ®Google Scholar
• Casanovas O , HicklinDJ, BergersG, HanahanD. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell8, 299–309 (2005).
   PubMed Web of Science ®Google Scholar
• Wesche J , HaglundK, HaugstenEM. Fibroblast growth factors and their receptors in cancer. Biochem. J.437, 199–213 (2011).
   PubMed Web of Science ®Google Scholar
• Lee JG , KoMK, KatEP. Endothelial mesenchymal transformation mediated by IL-1β-induced FGF-2 in corneal endothelial cells. Exp. Eye Res.95, 35–39 (2012).
   PubMed Web of Science ®Google Scholar
• Masola V , GambaroG, TibaldiEet al. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial–mesenchymal transition in renal tubular cells. J. Biol. Chem.287, 1478–1488 (2012).
   PubMed Web of Science ®Google Scholar
• Shang Y , CaiX, FanD. Roles of epithelial–mesenchymal transition in cancer drug resistance. Curr. Cancer Drug Targets13, 915–929 (2013).
   PubMed Web of Science ®Google Scholar
• Katoh M , NakagamaH. FGF receptors: cancer biology and therapeutics. Med. Res. Rev.34, 280–300 (2013).
   PubMed Web of Science ®Google Scholar
• Ornitz DM , ItohN. Fibroblast growth factors. Genome Biol.2(3), REVIEWS3005 (2001).
   PubMed Web of Science ®Google Scholar
• Belov AA , MohammadiM. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb. Perspect. Biol.5(6), a015958 (2013).
   PubMed Web of Science ®Google Scholar
• Coleman SJ , BruceC, ChioniAM, KocherHM, GroseRP. The ins and outs of fibroblast growth factor receptor signalling. Clin. Sci.127, 217–231 (2014).
   PubMed Web of Science ®Google Scholar
• Greenman C , StephensP, SmithRet al. Patterns of somatic mutation in human cancer genomes. Nature446, 153–158 (2007).
   PubMed Web of Science ®Google Scholar
• Katoh M . Cross-talk of WNT and FGF signaling pathways at GSK3β to regulate β-catenin and SNAIL signaling cascades. Cancer Biol. Ther.5, 1059–1064 (2006).
   PubMed Web of Science ®Google Scholar
• Porta C , PaglinoC, ImarisioIet al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology84, 115–122 (2013).
   PubMed Web of Science ®Google Scholar
• Gyanchandani R , Ortega AlvesMV, MyersJN, KimS. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma. Mol. Cancer Res.11, 1585–1596 (2013).
   PubMed Web of Science ®Google Scholar
• Narayanan V , PollyeaDA, GutmanJA, JimenoA. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Drugs Today (Barc.)49, 261–269 (2013).
   PubMed Web of Science ®Google Scholar
• Diaz-Padilla I , SiuLL. Brivanib alaninate for cancer. Expert Opin. Investig. Drugs20, 577–586 (2011).
   PubMed Web of Science ®Google Scholar
• Chou T , FinnRS. Brivanib: a review of development. Future Oncol.8, 1083–1090 (2012).
   PubMed Web of Science ®Google Scholar
• Bhide RS , CaiZ-W, ZhangY-Zet al. Discovery and preclinical studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J. Med. Chem.49, 2143–2146 (2006).
   PubMed Web of Science ®Google Scholar
• Ayers M , FargnoliJ, LewinA, WuQ, PlateroJS. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res.67, 6899–6906 (2007).
   PubMed Web of Science ®Google Scholar
• Huynh H , NgoVC, FargnoliJet al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res.14, 6146–6153 (2008).
   PubMed Web of Science ®Google Scholar
• Cai Z-W , ZhangY, BorzilleriRMet al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase iinhibitor (BMS-540215). J. Med. Chem.51, 1976–1980 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson PJ , QinS, ParkJWet al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase III BRISK-FL study. J. Clin. Oncol.31, 3517–3524 (2013).
   PubMed Web of Science ®Google Scholar
• Llovet JM , DecaensT, RaoulJLet al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized Phase III BRISK-PS study. J. Clin. Oncol.31, 3509–3516 (2013).
   PubMed Web of Science ®Google Scholar
• Siu LL , ShapiroJD, JonkerDJet al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J. Clin. Oncol.31, 2477–2484 (2013).
   PubMed Web of Science ®Google Scholar
• Dufies M , CassutoO, JacquelA, RobertG, AubergerP. Ponatinib circumvents all types of Imatinib resistance in chronic myelogenous leukemia cell lines. Cell Cycle12, 1645–1646 (2013).
   PubMed Web of Science ®Google Scholar
• Cortes JE , KimDW, Pinilla-IbarzJet al. A Phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N. Engl. J. Med.369, 1783–1796 (2013).
   PubMed Web of Science ®Google Scholar
• Wang X , KayA, AnakOet al. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib. J. Clin. Pharmacol.53, 14–20 (2012).
   Web of Science ®Google Scholar
• Chen Z-Y , ShiM, PengL-Xet al. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. J. Transl. Med.10, 245 (2012).
   PubMed Web of Science ®Google Scholar
• Hasinoff BB , WuX, NitissJL, KanagasabaiR, YalowichJC. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem. Pharmacol.84, 1617–1626 (2012).
   PubMed Web of Science ®Google Scholar
• Dubbelman AC , UpthagroveA, BeijnenJHet al. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemother. Pharmacol.70, 653–663 (2012).
   PubMed Web of Science ®Google Scholar
• Angevin E , Lopez-MartinJA, LinC-Cet al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin. Cancer Res.19, 1257–1268 (2013).
   PubMed Web of Science ®Google Scholar
• Keyes KA , MannL, CoxKet al. Circulating angiogenic growth factor levels in mice bearing human tumors using luminex multiplex technology. Cancer Chemother. Pharmacol.51, 321–327 (2003).
   PubMed Web of Science ®Google Scholar
• Sivanand S , Peña-LlopisS, ZhaoHet al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med.4, 137ra75 (2012).
   PubMed Web of Science ®Google Scholar
• Grisanzio C , SeeleyA, ChangMet al. Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J. Pathol.225, 212–221 (2011).
   PubMed Web of Science ®Google Scholar
• Huynh H , ChowPKH, TaiWMet al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J. Hepatol.56, 595–601 (2012).
   PubMed Web of Science ®Google Scholar
• Tai WT , ChengAL, ShiauCWet al. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1–mediated inhibition of STAT3. Mol. Cancer Ther.11, 452–463 (2011).
   PubMed Web of Science ®Google Scholar
• Chen KF , ChenH-L, LiuC-Yet al. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochem. Pharmacol.83, 769–777 (2012).
   PubMed Web of Science ®Google Scholar
• Pollock PM , GartsideMG, DejezaLCet al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene26, 7158–7162 (2007).
   PubMed Web of Science ®Google Scholar
• Dutt A , SalvesenHB, ChenTHet al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl Acad. Sci. USA105, 8713–8717 (2008).
   PubMed Web of Science ®Google Scholar
• Byron SA , GartsideM, PowellMAet al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS ONE7, e30801 (2012).
   PubMed Web of Science ®Google Scholar
• Konecny GE , KolarovaT, O’BrienNAet al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol. Cancer Ther.12, 632–642 (2013).
   PubMed Web of Science ®Google Scholar
• André F , BachelotT, CamponeMet al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res.19, 3693–3702 (2013).
   PubMed Web of Science ®Google Scholar
• Issa A , GillJW, HeidemanMRet al. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res.15, R8 (2013).
   PubMed Web of Science ®Google Scholar
• Kim KB , ChesneyJ, RobinsonD, GardnerH, ShiMM, KirkwoodJM. Phase I/II and pharmacodynamic study of Dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin. Cancer Res.17, 7451–7461 (2011).
   PubMed Web of Science ®Google Scholar
• Angevin E , GrünwaldV, RavaudAet al. A Phase II study of dovitinib (TKI258), an FGFR- and VEGFR inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J. Clin. Oncol.29(Suppl.), 4551 (2011).
   Google Scholar
• Motzer RJ , PortaC, VogelzangNet al. Phase 3 trial of dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomized Phase 3 trial. Lancet Oncol.15, 286–296 (2014).
   PubMed Web of Science ®Google Scholar
• Kang YK , YooC, RyooBYet al. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br. J. Cancer109, 2309–2315 (2013).
   PubMed Web of Science ®Google Scholar
• Sarker D , MolifeR, EvansTRet al. A Phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res.14, 2075–2081 (2008).
   PubMed Web of Science ®Google Scholar
• Byron SA , ChenH, WortmannAet al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia15, 975–988 (2013).
   PubMed Web of Science ®Google Scholar